LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
Liminatus Pharma agreed to acquire InnocsAI in an all-stock deal, issuing 1.6 billion shares at $0.20 each—over 35 times its current share count. LIMN rose 51% to $0.2844 in premarket trading. The deal would add CAR-T cancer therapy assets, including a candidate authorized for a Phase 1/2a study in South Korea. Liminatus reported $1.91 million in cash and warned of “substantial doubt” about its ability to continue.